Fig.1A



Counts
0 10 20 30 40 50
10^0 10^1 10^2 10^3 10^4

Fig.1B



Counts
0 10 20 30 40 50
10^0 10^1 10^2 10^3 10^4

Fig.2A



100
80
60
40
20
0
organ survival (%)
0
25
50
75
100
125
150
time (days after heart transplantation)
LEW > DA; untreated
LEW > DA; TAIC (LEW), day -7
CAP > DA; untreated
CAP > DA; TAIC (LEW), day -7
LEW > LEW; untreated
LEW > LEW; TAIC (LEW), day -7



Fig. 2B



Fig. 2C

Fig.2D



% donor cells (I1.69+)
25
20
15
10
5
0
0
20
40
60
80
100
120
140
160
180
200
time (days after TAIC administration)
rat 1
rat 2
rat 3
rat 4

Fig.3



100
80
60
40
20
0
organ survival (%)
0
25
50
75
100
125
150
time (days after transplantation)
LEW > DA; untreated
LEW > DA; CSA
LEW > DA; CSA + TAIC
LEW > DA; TAIC
CAP > DA; CSA + TAIC
(LEW-derived)

Fig. 4A



surviving animals (%)
100
80
60
40
20
0
0
25
50
75
100
125
150
time (days after transplantation)
DA > LEW; untreated
DA > LEW; TAIC i.v. at days -7 and -1

Fig.4B




100
80
60
40
20
0
surviving animals (%)
0
25
50
75
100
125
150
time (days after transplantation)
DA > LEW, untreated
DA > LEW; TAIC i.v. at days -7 and -1

Fig.4C


100
80
60
40
20
0
organ survival (%)
0
25
50
75
100
125
150
time (days after transplantation)
DA > LEW, untreated
DA > LEW; TAIC i.v. at days -7 and -1




Fig. 4D-2 LEW -> LEW, POD 14




Fig. 4D-4 TAIC treated, POD 14

Fig. 4D-1 kidney control

Fig. 4D-3 DA -> LEW, untreated, POD 14




Fig. 4E-1 Fig. 4E-2 Fig. 4E-3



Fig. 4F

Fig.5A



100
80
60
40
20
0
organ survival (%)
0
25
50
75
100
125
150
time (days after transplantation)
DA > LEW; untreated
DA > LEW; CSA + TAIC
CAP > LEW; untreated
CAP > LEW; CSA + TAIC
BN > LEW; untreated
BN > LEW; CSA + TAIC

Fig. 5B




organ survival (%)
100
80
60
40
20
0
0
25
50
75
100
125
150
time (days after transplantation)
monocytes; untreated
monocytes; M-CSF treated
monocytes; γ-IFN treated
monocytes; M-CSF + γ-IFN treated

Fig. 6A


100
80
60
40
20
0
organ survival (%)
0
50
100
150
200
250
300
350
time (days after transplantation)
CSA, AZA, STE
CSA, AZA, STE, BM, WBI
CSA, AZA, STE, TAIC




Fig. 6B-2

Fig. 6B-1

Fig.7



responder A : stimulator B
^{3}[H] TdR (cpm x 10^3)
50
40
30
20
10
0
Ly
GM-7-negative
GM-7-positive

Fig.8



suppressor function
PhaLy + „Mo“ + 1-MT
PhaLy + „Mo“
PhaLy + „Mo+Ly“ + 1-MT
PhaLy + „Mo+Ly“
PhaLy
Ly
0
2500
5000
7500
10000
12500
15000
17500
20000
22500
c.p.m.

Fig.9



antigen-positive cells (%)
100
75
50
25
0
CD 14+
CD 2+
CD3+/CD14+
Mo d 0
Mo d 5
Mo + Ly d 0
Mo + Ly d 5

Fig.10A




Fig.10C




Fig.10B

